The U.S. Food and Drug Administration (FDA) is moving closer to a potentially historic moment: the approval of the first psychedelic medicine. Against this backdrop, the agency held a public hearing on September 14 to discuss how psychedelic therapies should be administered, monitored, trained for, and studied after approval.
A central issue was access. If a psychedelic medicine receives FDA approval, who should be permitted to administer it? The answer could directly influence how easily patients with depression, anxiety and other mental health conditions can receive these treatments.
The emerging pharmaceutical model is different from the psychedelic programs associated with Oregon and Colorado, where substances such as psilocybin are often used alongside psychotherapy. Companies including Compass Pathways and Definium Therapeutics are developing regulated medicines designed to be given in supervised clinical settings.
Their approach generally involves a healthcare professional acting as a dosing session monitor (DSM) while the patient undergoes the psychedelic experience. The model is intended to demonstrate the medicine's therapeutic effect while creating a controlled environment for safety and monitoring.
However, several speakers argued that psychotherapy should not be separated from psychedelic treatment. Geoff Bathje, a clinical psychologist and co-founder of Sana Healing Collective, said research with ketamine and other psychedelics indicates that treatment may be more effective when combined with therapy.
The question then becomes broader than simply approving a drug. The FDA may also need to consider who should supervise treatment, what training they require and what level of medical expertise should be available when patients experience complications.
Psychiatrist Rajan Dunne of Sheppard Pratt argued that psychedelic treatment for psychiatric conditions should involve clinical oversight by psychiatrists. His position reflects concerns that patients may require detailed psychiatric assessment before treatment and expert management if unexpected reactions occur.
At the same time, other speakers argued that creating an entirely new psychedelic workforce may unnecessarily restrict access. Nurse practitioner Tina Braddock said nurses already have the licensing, clinical training and availability needed to support safe psychedelic care.
Training and credentialing therefore emerged as another major issue. Several professionals involved in psychedelic education called for standardized and transparent training requirements, while others emphasized using existing healthcare professionals rather than creating a separate system.
Geography could also become an important access barrier. FDA guidance issued in July states that when the lead monitor is not a physician, an on-call physician must be able to reach the patient within 15 minutes. Speakers warned that such a requirement could make treatment difficult to provide in rural and remote areas.
The hearing also brought a strong reminder that enthusiasm for psychedelic medicines must be balanced with scientific evidence. Kevin Sabet, a former White House advisor on drug control policy, cautioned against allowing political attention and cultural enthusiasm to move the field faster than the underlying science.
He pointed to concerns around small phase 3 trial populations, methodological weaknesses and the possibility of negative findings receiving less attention. These concerns are particularly important because psychedelic medicines are being developed for conditions affecting very large patient populations.
Safety was another major focus. Speakers raised concerns about cardiac risks, patient screening and the potential for misconduct during vulnerable psychedelic experiences. The death of 21-year-old Shira, discussed by Susan Taymor Sagy of the Coalition for Psychedelic Safety and Education, brought the consequences of inadequate safeguards into sharp focus.
The discussion ultimately showed that psychedelic drug approval will involve much more than proving whether a compound works. Regulators will have to consider the entire treatment ecosystem, including patient selection, supervision, workforce training, emergency response, therapy and long-term monitoring.
For developers such as Compass Pathways and Definium Therapeutics, this creates a new strategic challenge. Clinical efficacy may open the door to approval, but practical delivery, safety standards and affordability could determine whether these medicines can actually reach patients at scale.
The potential approval of a psychedelic medicine would therefore represent a historic shift in mental healthcare. The FDA's decisions could establish a framework that influences not only the first approved psychedelic therapy but also how an entire class of medicines is developed and delivered.
About the FDA
The U.S. Food and Drug Administration (FDA) is the federal agency responsible for protecting public health by evaluating the safety and effectiveness of medicines, medical products and other regulated healthcare products. Its decisions can significantly influence how new therapies enter clinical practice in the United States.
Reference:
https://www.fda.gov/drugs/resources-drugs/psychedelic-drugs
https://www.towardshealthcare.com/